Drug development advisory and execution support for biotech companies
Many programs don’t fail because of the science.
They fail at the inflection points where breakthrough science meets critical business decisions. We call these “Apex Moments” - moments when science, strategy, and execution must move as one.
Apex Life Sciences was built for those moments.
Three imperfect options.
None of them built for the
Apex Moments.
The life sciences advisory landscape forces a choice no program should have to make.
CROs provide operational scale without strategic depth.
Strategy firms deliver frameworks without the capability to implement them.
Generalists offer broad coverage without the scientific credibility that rare disease demands.
Apex occupies the space none of them can: scientifically rigorous, strategically sharp, and close enough to your program to act - and to execute alongside you.
The point where programs succeed - or don’t.
Every drug development program has moments where science, strategy, and execution must align simultaneously. Miss any one of them - and a program that deserved to succeed, fails. Not because of the biology. Because of a decision that was made without the right partner in the room.
A Phase 1b trial that enrolled the wrong patients because selection criteria weren’t revisited after pre-IND feedback will generate noise, not signal. The target was sound. The strategy and execution wasn’t.
We identify that friction before it becomes a failure.
What we do
-
Indication Selection · Target Product Profile (TPP) · Asset Strategy
From early indication selection and TPP development to pre-IND regulatory strategy - defining the path before the critical decisions narrow it.
-
Early Drug Development & Strategy · Rare Disease · Regulatory Pathway
The scientific, regulatory, and human complexity of rare disease demands more than a generalist approach. We bring the specialised depth these programs require.
-
Integrated Development Planning · Critical Path & Decision Support · Cross-functional Integration
A development program spans the whole asset — CMC, nonclinical, clinical and regulatory — not just the trial. We build the integrated development plan, hold the critical path across functions, and prepare the decisions your board actually has to make.
-
CRO & Vendor Selection · Performance Management · Site Strategy & Clinical Operations · KOL Mapping
Sponsors rarely lose control of a trial during conduct — they lose it at selection. We run the RFI/RFP, hold the CRO to a scope specific enough to enforce, and make sure execution lives up to the science.
-
Corporate Structure · Interim Leadership · Investor Readiness · Operational Infrastructure
Building the corporate and operational foundation that carries promising science through financing and partnerships.
The scientific, regulatory, and human complexity of rare disease demands more than a generalist approach. We bring the specialised depth these programs require.
The Team
Apex is built around its founders, Olivier Van de Steen and Kevin Clement, and operates as a focused senior team - part of your team, not a consulting layer between your program and the people who know it. Every engagement is led by a founding partner, backed by a network of independent specialists when the program calls for it. You get the depth, the accountability, and the precision - directly.
